What are the " several, [specific], backup plans[BMY has] for Opdivo in NSCLC.", in addition to what Titan V posted:
"BMY - Also being released this quarter is phase 1 data from Opdivo + HS-110 in NSCLC with $HTBX. Although tiny, this trial is listed as one of the select combination trials in the Nature article you shared last week."